29/11/2017

European Commission launches: “What I need to know about Biosimilar Medicines – Information for patients”, in 23 EU languages

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
06/06/2017

EuropaBio launches recommendations to enhance transparency of biosimilar labels

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
27/05/2017

Biosimilar SmPC Recommendations

This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
Become a member